Last updated: June 3, 2026
Suppliers for ORIAHNN (copackaged): who makes and supplies the products, components, and logistics?
ORIAHNN (elagolix/estradiol/norethindrone acetate; copackaged) is supplied by AbbVie, and the U.S. commercial supply chain is structured around a copackaged “kit” concept. Public-facing supplier disclosures typically identify the commercial sponsor (AbbVie) and, for manufacturing and packaging, the FDA-listed label/manufacturer entities and site-level “manufactured for/marketed by” or “packaged by” parties tied to the NDA label and supplements.
What is the ORIAHNN copackaged supply model?
ORIAHNN is marketed as a copackaged regimen, meaning the product is composed of multiple components provided together in a single patient pack. From a supplier standpoint, this usually translates into:
- Drug substance manufacture (elagolix, estradiol, norethindrone acetate) and drug product manufacture (tablet and/or capsule strengths depending on component)
- Component packaging into the copack
- Final kit assembly, labeling, and distribution
Because the user request is explicitly “suppliers,” the only defensible answer is the supplier entities that are actually identified on the U.S. product labeling and FDA drug product records (e.g., “manufactured for,” “packaged by,” and NDA holder entities). Without those label-level party names, any attempt to name specific suppliers risks being incorrect.
What companies are listed as manufacturers or suppliers on ORIAHNN labeling?
ORIAHNN’s key supplier identities are the entities listed on the FDA-approved prescribing information and associated product labeling for:
- “Manufactured for” (typically the NDA/label holder supply manufacturer relationship)
- “Packaged by” or “Distributed by” (distribution and final packaging entities)
- “Manufactured by” (site-specific manufacturer, where different from “packaged by”)
Those label-level entities are the correct “suppliers” for business purposes because they connect directly to regulatory manufacturing responsibilities and contractual supply.
What patents protect ORIAHNN copackaged components and how does that affect supplier access?
ORIAHNN’s copackaged format can create additional constraints on suppliers, because a generic or alternative pack must match the approved regimen composition and dose schedule. The supplier landscape is tied to:
- Orange Book listed drug product and method patents for the NDA
- Formulation and process patents that can lock in specific excipients, coatings, and manufacturing processes
- Patents that cover the regimen dosing schedule if the kit structure is claimed
If you are assessing supplier alternatives or second-source manufacturing, the controlling question is whether there are viable non-infringing manufacturing routes for the specific kit components.
When does ORIAHNN lose exclusivity and how does that change the supplier pool?
Exclusivity and patent expiry affect whether additional contract manufacturers can enter as suppliers for an authorized generic or eventual alternative products. The supplier pool usually widens after:
- Loss of regulatory data exclusivity and patent protection barriers
- Resolution of any patent litigation and entry pathways
What is the Orange Book status of ORIAHNN and which entities are tied to the NDA?
The Orange Book status is the authoritative map of which “product” entities and patent estates attach to:
- Each strength/component (where separately listed)
- The reference listed drug and any listed patents covering formulation and method-of-use
How strong is the patent estate for ORIAHNN copackaged regimens and what does it mean for alternative suppliers?
For copackaged regimens, patent strength can be higher operationally if:
- Multiple components have overlapping patent families
- Regimen-specific claims exist that complicate “near-equivalent” packaging substitutions
- Manufacturing process claims limit reengineering of the kit assembly or component manufacturing
What generic entry risks exist for ORIAHNN copackaged products?
If generic or authorized alternatives exist in the future, the key supplier risks are:
- Inability to replicate the exact regimen structure without triggering formulation/process/regimen patents
- Bottlenecks in obtaining the required copack packaging format and patient instructions
- Regulatory delays if manufacturing sites are not validated for kit assembly
What patent litigation affects ORIAHNN suppliers?
If any Paragraph IV or other challenges have been filed against ORIAHNN, litigation outcomes can determine:
- Which applicants can legally supply the market
- Timing for launch and contract award decisions
- Whether settlement agreements create licensed or restricted-scope entry
How does ORIAHNN compare with other ABBVIE women’s health regimens on supplier structure?
Within women’s health, copackaged regimens are often built around:
- Multiple component manufacturing lines
- Dedicated packaging and kit assembly vendors
- QA and labeling supply chains that are more rigid than single-entity tablets
Supply chain complexity is typically higher than for single-entity drugs, which increases the importance of label-identified packaging and manufacturing suppliers.
Key Takeaways
- ORIAHNN is a copackaged regimen; “suppliers” should be limited to the manufacturing/packaging/distribution entities explicitly identified on the FDA-approved labeling and related FDA drug product records.
- Copack packaging increases operational IP and regulatory constraints, which can narrow feasible alternative suppliers until exclusivity and patent barriers clear.
- Patent estate and Orange Book listings govern whether alternative suppliers can legally manufacture and supply the regimen components and copack structure.
FAQs
- Who is the NDA holder and marketed-by entity for ORIAHNN copackaged products in the U.S.?
- Which entities are listed on ORIAHNN labeling as “manufactured for,” “packaged by,” or “distributed by”?
- Are ORIAHNN components manufactured by the same site as the final copack assembly?
- What Orange Book patents are listed for the ORIAHNN regimen, and do any cover kit assembly or regimen dosing schedules?
- If a generic or authorized alternative enters, what supplier roles are required to replicate copackaging and labeling under FDA rules?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Product search for ORIAHNN).
- U.S. Food and Drug Administration. Labeling (Prescribing Information) for ORIAHNN (elagolix/estradiol/norethindrone acetate).
- DailyMed. ORIAHNN (elagolix/estradiol/norethindrone acetate) prescribing information and labeling.
